Top Ten most popular articles on Pharmafile.com this week

pharmafile | March 10, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing top ten 

The past week in the industry has brought much hope for patients with the news of significant research data developments in cancer, along with a range of new treatment approvals and even NICE’s announcement that 14 drugs previously only available through the Cancer Drugs Fund are now routinely available on the NHS.

10. FDA and NICE approve of first new hyperparathyroidism drug in 12 years

The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients of the disease in twelve years.

9. Gene therapy: Advanced treatments for a new era

Aranca discusses the considerable advances that have occurred in the last few years in gene therapy.

8. Lilly posts impressive psoriasis results in comparison study

Eli Lilly has revealed strong results in a study comparing its psoriasis treatment, Taltz (ixekizumab), to Johnson & Johnson’s Stelara. The study was held over a duration of 52 weeks, with Taltz displaying high proportion of response from patients.

7. Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use

NICE has approved the transferral of 14 drugs across 18 indications from the Cancer Drugs Fund to routine use across the NHS.

6. Diabetes drug could be key to treating aggressive breast cancer, research suggests

Research has identified that the function of metabolic enzyme AKR1B1 is key to the progression of aggressive ‘basal-like’ breast cancer, meaning an existing diabetes drug which inhibits it may be useful in fighting the disease.

5. Negotiating the EU pricing system: How the financial crisis has encouraged closer-knit cooperation between member states

Ben Hargreaves looks at the pricing debate occurring within Europe and how it could lead to closer relations between countries within the EU.

4. Phase 3 data for Janssen psoriasis drug shows efficacy over Humira

Phase 3 data for the human monoclonal antibody guselkumab in the treatment of adults with moderate to severe plaque psoriasis, showed significant efficacy compared to Abbvie’s blockbuster drug Humira.

3. UK High Court rules against AbbVie’s Humira patents

The UK High Court has ruled that two of AbbVie patents, related to dosing regimens for rheumatoid arthritis, psoriasis and psoriatic, were invalid. The case was brought by claimants Samsung Bioepis, Biogen and Fujifilm Kyowa Kirin Biologics.

2. Osteoporosis drugs potentially causing long-term bone weakness

Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from scientists at Imperial College London has found.

1. FDA green lights AstraZeneca type-2 diabetes drug

AstraZeneca has announced that its type-2 diabetes treatment Qtern (10mg dapagliflozin and 5mg saxagliptin) has received the approval of the US Food and Drug Administration.

Related Content


Top Ten most popular articles on Pharmafile.com this week

As the year winds to a close, excitement is rising around the efficacy and availability …


Top Ten most popular articles on Pharmafile.com this week

The top ten news stories this week focus on herd immunity, as the Director of …


Pharmafile.com’s weekly COVID-19 news round-up

The coronavirus news this week focuses on the development of treatments to alleviate symptoms of …

Latest content